Loading...
Loading...
announced in an
8-K filing on Wednesday that it plans on terminating its commercial supply and license agreements with
VIVUS, Inc.VVUS related to its right to commercialize Avanafil.
Endo International received exclusive rights to commercialize Avanafil for any urological disease in the US, Canada, and related territories. The company noted that the effective date of the termination will be June 30, 2016.
Shares of Vivus were trading lower by 1 percent at $1.00 early Thursday morning.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in